pets-20240213

0001040130-24-000010.txt : 20240215 0001040130-24-000010.hdr.sgml : 20240215 20240215112005 ACCESSION NUMBER: 0001040130-24-000010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PETMED EXPRESS INC CENTRAL INDEX KEY: 0001040130 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 650680967 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28827 FILM NUMBER: 24642784 BUSINESS ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 BUSINESS PHONE: (561) 426-4444 MAIL ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 8-K 1 pets-20240213.htm 8-K pets-20240213

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024

PetMed Express, Inc.

(Exact name of registrant as specified in its charter)

Florida

000-28827

65-0680967

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

420 South Congress Avenue, Delray Beach, Florida 33445

(Address of principal executive offices) (Zip Code)

(561) 526-4444

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	PETS	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed in the Notification of Late Filing on Form 12b-25 of PetMed Express, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on February 9, 2024, the Company determined that it was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”) by the prescribed due date as a result of the restatement of certain of the Company’s financial statements (the “Restatement”). The Restatement is more fully described in the Company’s Current Report on Form 8-K filed with the SEC on February 8, 2024.

On February 13, 2024, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

While the Company can provide no assurances as to timing, the Company is working diligently to complete the Restatement and plans to file the Form 10-Q as soon as practicable to regain compliance with the Listing Rule.

On February 15, 2024, the Company issued a press release announcing its receipt of the Notice. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

99.1 – Press release dated February 15, 2024.

104 – Cover Page Interactive Data File (formatted as Inline XBRL).

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: the expected adjustments to the Company’s financial statements, including the estimated amount and impact of adjustments on the Company’s financial statements, and the potential for additional adjustments to the Company’s financial statements resulting from the restatement described above. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2023, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

EXHIBIT INDEX


Exhibit No.						Description

99.1						Press release dated February 15, 2024
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 15, 2024


			PETMED EXPRESS, INC.

			By:			/s/ Christine Chambers
			Name:			Christine Chambers
			Title:			Chief Financial Officer, Treasurer and Secretary

EX-99.1 2 pets-2024215xexx991notific.htm EX-99.1 Document

Exhibit 99.1

PetMeds® Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

DELRAY BEACH, Fla, Feb 15, 2024 – PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) received on February 13, 2024, a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days and, following receipt of such plan, Nasdaq may grant an extension of up to 180 calendar days from the Form 10-Q due date, or until August 7, 2024, for the Company to regain compliance. On February 9, 2024, the Company filed a Notification of Late Filing on Form 12b-25 indicating that it was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”) by the prescribed due date as a result of the restatement of certain of the Company’s financial statements (the “Restatement”). The Restatement is more fully described in the Company’s Current Report on Form 8-K filed with the SEC on February 8, 2024.

ABOUT PETMEDS

Founded in 1996, PetMeds is Your Trusted Pet Health Expert, delivering pet medications, food, health services and other products direct to the consumer at PetMeds.com and through its toll-free number (1-800-PetMeds). PetMeds aims to be the most trusted pet health expert by providing incredible care and services that are affordable to the broadest group of pet parents--because every pet deserves to live a long, happy, healthy life. For more information, please visit www.petmeds.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: statements regarding the Company’s ability to complete the filing of the Form 10-Q within the anticipated time period; the Company’s ability to regain compliance with Nasdaq listing standards; and the time required to complete the Restatement of the Company’s financial statements. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2023, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

PETMEDS INVESTOR RELATIONS CONTACT

Brian M. Prenoveau, CFA

MZ Group

561-489-5315

investor@petmeds.com

PETMEDS MEDIA CONTACT

Exhibit 99.1 Page 1 of 1

Mary Eva Tredway

Butin PR

maryeva@butinpr.com

Exhibit 99.1 Page 2 of 1

EX-101.SCH 3 pets-20240213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pets-20240213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 pets-20240213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 15, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 13, 2024
Entity Registrant Name	PetMed Express, Inc.
Entity Incorporation, State or Country Code	FL
Entity File Number	000-28827
Entity Tax Identification Number	65-0680967
Entity Address, Address Line One	420 South Congress Avenue
Entity Address, City or Town	Delray Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33445
City Area Code	561
Local Phone Number	526-4444
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	PETS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001040130
Amendment Flag	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.1800petmeds.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pets-20240213.htm pets-20240213.xsd pets-20240213_lab.xml pets-20240213_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pets-20240213.htm": { "nsprefix": "pets", "nsuri": "http://www.1800petmeds.com/20240213", "dts": { "inline": { "local": [ "pets-20240213.htm" ] }, "schema": { "local": [ "pets-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pets-20240213_lab.xml" ] }, "presentationLink": { "local": [ "pets-20240213_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.1800petmeds.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pets-20240213.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pets-20240213.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001040130-24-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001040130-24-000010-xbrl.zip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end XML 16 pets-20240213_htm.xml IDEA: XBRL DOCUMENT 0001040130 2024-02-15 2024-02-15 0001040130 false 8-K 2024-02-13 PetMed Express, Inc. FL 000-28827 65-0680967 420 South Congress Avenue Delray Beach FL 33445 561 526-4444 false false false false Common Stock, par value $.001 per share PETS NASDAQ false